Abstract
We determined the orexin concentration in cerebrospinal fluid (CSF-OX) in two patients with subacute sclerosing panencephalitis who underwent intracerebroventricular (ICV) α-interferon (IFN-α) therapy. In these patients, CSF-OX were in the normal range before ICV administration of IFN-α, and it decreased to undetectable levels after the initiation of IFN-α therapy. It was reported that the production of prepro-OX, which is a precursor of OX, was prevented when IFN-α was given to the gene promoter region of prepro-OX. These results suggest that the production of OX may be suppressed by inhibition of promotor activity when IFN-α is given to the cerebral ventricle in humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
